tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Precigen’s PAPZIMEOS Receives FDA Approval for RRP

Story Highlights
  • Precigen’s PAPZIMEOS received FDA approval for treating adults with RRP.
  • PAPZIMEOS is poised to become the standard-of-care for RRP, impacting Precigen’s market position.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Precigen’s PAPZIMEOS Receives FDA Approval for RRP

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Precigen ( (PGEN) ) is now available.

On August 18, 2025, Precigen, Inc. announced that its product PAPZIMEOS received FDA approval as the first and only therapy for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease. This approval positions PAPZIMEOS as a potential standard-of-care treatment, offering a new paradigm for managing RRP, which was previously treated mainly through surgical interventions. The approval is expected to significantly impact Precigen’s market positioning and provide a new therapeutic option for the estimated 27,000 adult RRP patients in the US.

The most recent analyst rating on (PGEN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.

Spark’s Take on PGEN Stock

According to Spark, TipRanks’ AI Analyst, PGEN is a Neutral.

Precigen’s overall stock score is primarily impacted by its weak financial performance, which poses significant risks. However, strong technical momentum and positive corporate events provide some optimism. The valuation remains unattractive due to ongoing losses.

To see Spark’s full report on PGEN stock, click here.

More about Precigen

Precigen, Inc. operates in the biotechnology industry, focusing on developing innovative gene and cell therapies. The company is primarily engaged in creating treatments for complex diseases, with a notable emphasis on immunotherapies and genetic medicines.

Average Trading Volume: 5,164,658

Technical Sentiment Signal: Buy

Current Market Cap: $876M

See more data about PGEN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1